Inicio>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>m-PEG10-acid

m-PEG10-acid

Catalog No.GC67238

m-PEG10-acid es un conector ADC de PEG de 10 unidades no escindible que se utiliza en la síntesis de conjugados de anticuerpo-fármaco (ADC). m-PEG10-acid también es un conector PROTAC basado en PEG que se puede usar en la síntesis de PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

m-PEG10-acid Chemical Structure

Cas No.: 2409969-94-2

Tamaño Precio Disponibilidad Cantidad
1mg
1.026,00 $
Disponible
5mg
2.952,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

m-PEG10-acid is a non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. m-PEG10-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[2].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

[1]. John F. Donovan et al. Pegylated prodrugs of phenolic trpv1 agonists. WO2020023794A1.
[2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

Reseñas

Review for m-PEG10-acid

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for m-PEG10-acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.